Tamsulosin 0.4 mg
Pro Research Analysisby 
Searched over 200M research papers
Tamsulosin 0.4 mg: Efficacy, Safety, and Impact on Sexual Function
Efficacy of Tamsulosin 0.4 mg in Treating Benign Prostatic Hyperplasia (BPH)
Tamsulosin 0.4 mg once daily has been extensively studied for its efficacy in treating lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Multiple studies have demonstrated that tamsulosin significantly improves urinary flow rates and reduces symptom scores compared to placebo. For instance, a meta-analysis of two European studies showed that tamsulosin improved maximum urinary flow rate by 1.6 ml/s (16%) compared to 0.6 ml/s (6%) in the placebo group, and reduced the total Boyarsky symptom score by 35.1% compared to 25.5% in the placebo group4. Another study confirmed these findings, showing significant improvements in both maximum urinary flow rate and symptom scores with tamsulosin treatment5.
Safety and Tolerability of Tamsulosin 0.4 mg
Tamsulosin 0.4 mg is generally well-tolerated in both younger and older patients with LUTS suggestive of BPH. The incidence of adverse events, including drug-related and serious adverse events, was similar between tamsulosin and placebo groups, with no significant differences observed between younger and older patients2. Additionally, tamsulosin did not cause clinically significant changes in blood pressure or pulse rate, making it a safe option for patients with BPH4 5.
Impact on Sexual Function
The effect of tamsulosin 0.4 mg on sexual function has been a point of interest in clinical studies. One study compared tamsulosin with placebo and alfuzosin, another alpha-blocker, and found that abnormal ejaculation occurred more frequently in patients treated with tamsulosin than those receiving placebo (p = 0.045). However, the incidence was similar between tamsulosin and alfuzosin groups. Importantly, abnormal ejaculation was not perceived as a major problem by patients and was reversible upon drug withdrawal. There were no significant differences in the occurrence of decreased libido or impotence between tamsulosin and placebo or alfuzosin1.
Comparative Efficacy of Tamsulosin 0.4 mg and 0.2 mg
In Asian populations, studies have compared the efficacy of tamsulosin 0.4 mg and 0.2 mg. Results indicated that while both dosages were superior to placebo, tamsulosin 0.4 mg was more effective in improving the International Prostate Symptom Score (IPSS)6. However, a network meta-analysis suggested no significant difference in efficacy between the two dosages, indicating that 0.2 mg might be a sufficient initial dose for Asian patients7.
Conclusion
Tamsulosin 0.4 mg once daily is an effective and well-tolerated treatment for LUTS associated with BPH. It significantly improves urinary flow rates and reduces symptom scores without causing significant adverse effects. While it may cause abnormal ejaculation in some patients, this side effect is generally not severe and is reversible. For Asian patients, both 0.2 mg and 0.4 mg dosages are effective, with the higher dose providing slightly better symptom improvement. Overall, tamsulosin 0.4 mg remains a reliable option for managing BPH symptoms.
Sources and full results
Most relevant research papers on this topic
Tamsulosin 0.4 mg Once Daily: Effect on Sexual Function in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
Tamsulosin 0.4 mg once daily is well-tolerated and has no overall negative impact on sexual function compared to placebo or alfuzosin, and may even improve it compared to placebo.
RCT
Large Human Trial
Highly CitedTamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
Tamsulosin is well-tolerated and suitable for use in both older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
RCTLarge Human TrialA second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group.
Tamsulosin is a safe and effective treatment for relieving symptoms of benign prostatic hyperplasia in men with moderate to severe symptoms, with no first dose effect and no significant orthostatic hypertension.
RCTLarge Human TrialHighly CitedTamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Tamsulosin 0.4 mg once daily is safe, well-tolerated, and improves symptoms and urinary flow rate in patients with benign prostatic obstruction (symptomatic BPH).
Meta-AnalysisHighly CitedTamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.
Tamsulosin 0.4 mg once daily is a safe, well-tolerated, and effective treatment for improving symptoms and urinary flow rate in patients with symptomatic benign prostatic hyperplasia.
RCTHighly CitedEfficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial
Tamsulosin 0.4 mg is more effective than 0.2 mg in improving total prostate symptom score and has favorable efficacy and tolerability in Asian men with symptomatic benign prostatic hyperplasia.
RCTLarge Human TrialEvidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients
The initial dose of tamsulosin for Asian benign prostate hyperplasia patients should be 0.2 mg, as there is no significant difference in efficacy between 0.2 and 0.4 mg.
Meta-Analysis
Rigorous JournalA dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).
Tamsulosin 0.4 mg and 0.6 mg significantly improve urinary flow rate and reduce lower urinary tract symptoms in patients with benign prostatic obstruction, while being well-tolerated and well-tolerated by patients.
RCTA randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
The combination of tamsulosin and vardenafil for 12 weeks was well-tolerated and more effective in improving lower urinary tract symptoms and erectile function compared to tamsulosin alone.
RCTHighly CitedDistal Ureteric Stones and Tamsulosin: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial.
Tamsulosin showed no overall benefit for patients with distal ureteric stones less than 10 mm in diameter, but may increase passage for large stones (5 to 10 mm).
RCTLarge Human TrialHighly Cited